Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 25, 2021Current Medical Research and Opinion

Effects of sacubitril/valsartan on clinical symptoms, echocardiographic parameters, and outcomes in HFrEF and HFmrEF patients with coronary heart disease and chronic kidney disease

View Full Paper
Ask AI
Bookmark
Share

Why the study?

The comparative effects of ARNI on clinical symptoms, echocardiographic parameters, and outcomes in HFrEF versus HFmrEF patients with coronary heart disease and chronic kidney disease were not established.

Does sacubitril/valsartan improve clinical symptoms, echocardiographic parameters, and outcomes differently in HFrEF compared to HFmrEF patients with coronary heart disease and chronic kidney disease?

Population

127 HFrEF and HFmrEF patients with coronary heart disease and chronic kidney disease

Comparison

Sacubitril/valsartan in HFrEF vs HFmrEF

Design

Retrospective observational study

Follow-up

95.4 ± 57.8 days (8 months)

Authors

DRDominick Mkombozi RaphaelZLZhiyu LiuZJZhi Jin

Discussion

Loading...

Member takes

Overview

Suggests greater LVEF benefit from sacubitril/valsartan in HFrEF versus HFmrEF with CHD/CKD; hypothesis-generating, needs RCT confirmation.

Structured PICO

Does sacubitril/valsartan improve clinical symptoms, echocardiographic parameters, and outcomes differently in HFrEF compared to HFmrEF patients with coronary heart disease and chronic kidney disease?

P
Population
127 patients with heart failure with reduced ejection fraction (HFrEF) and heart failure with mid-range ejection fraction (HFmrEF) with concomitant coronary heart disease and chronic kidney disease
I
Intervention
Sacubitril/valsartan
C
Comparator
HFmrEF patients receiving sacubitril/valsartan (compared against HFrEF patients)
O
Outcome
Clinical symptoms, echocardiographic parameters, and outcomes (cardiovascular death and hospitalization)composite

Sacubitril/valsartan provides greater improvements in morphofunctional remodeling parameters and clinical symptoms in HFrEF patients compared to HFmrEF patients with concomitant coronary heart disease and chronic kidney disease.

Cite This Study

Raphael et al. (2021) studied this question.

synapsesocial.com/papers/6a7ddfa0b590a867d6a13ff2https://doi.org/10.1080/03007995.2021.1908243
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Sacubitril/valsartan improves both functional and echocardiographic parameters in patients with chronic heart failure with reduced ejection fraction2019 · 19 citations
  2. 2Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction2020 · 35 citations
  3. 3Sacubitril/valsartan treatment improved the clinical outcome and reduced the hospitalization rate in three patients with chronic heart failure: a case series2019 · 2 citations
  4. 4Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation2019 · 338 citations
  5. 5Sacubitril/Valsartan Improves Autonomic Function and Cardiopulmonary Parameters in Patients with Heart Failure with Reduced Ejection Fraction2020 · 28 citations